Table 1.
Quality assessment for the 17 included articles based on Newcastle–Ottawa quality assessment scale.
| Selection |
Comparability |
Exposure |
||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Refs. | Inclusion criteria | Sample size >50 | Endpoint | Anatomical location | Enneking stage | Chemotherapy | Local recurrence | 5-year overall survival | Metastatic | NOS |
| Abudu et al. [12] | * | – | * | * | * | * | * | * | * | 8* |
| Bacci et al. [13] | * | – | * | * | * | * | * | – | – | 6* |
| Bacci et al.b[14] | * | * | * | – | – | * | * | * | * | 7* |
| Bramer et al. [15] | * | * | * | * | – | * | * | – | – | 6* |
| Ferguson et al. [16] | * | – | * | * | – | * | * | – | – | 5* |
| Guo et al. [17] | * | – | * | * | – | * | * | – | * | 6* |
| Hegyi et al. [18] | * | * | * | – | – | * | * | * | * | 7* |
| Jiang et al. [19] | * | * | * | * | * | * | * | – | – | 8* |
| Kim et al. [20] | * | – | * | * | – | * | * | – | – | 5* |
| Ma et al. [21] | * | * | * | * | – | * | – | * | – | 6* |
| Mavrogenis et al. [22] | * | – | * | * | – | * | * | – | * | 6* |
| Niu et al. [23] | * | – | * | * | * | * | * | * | * | 8* |
| Robert et al. [24] | * | * | * | * | – | – | * | * | – | 6* |
| Scully et al. [25] | * | * | * | * | * | * | * | * | – | 8* |
| Xu et al. [26] | * | * | * | * | * | * | * | * | – | 8* |
| Zhang et al. [27] | * | – | * | * | * | * | * | – | * | 7* |
| Zhao et al. [28] | * | * | * | * | * | * | * | – | – | 7* |